innovation in heart failure drug development – is there .../media/informa-shop-window/... ·...
TRANSCRIPT
Innovation in Heart Failure Drug Development – Is There Enough?
JAKE MATHONPrincipal Analyst, Citeline
PharmaprojectsPharma intelligence |
PharmaprojectsPharma intelligence |
2
2
Heart failure is a chronic condition that is of major concern to the healthcare community. 5.8 million Americans and 23 million people globally are estimated to have heart failure¹. 400,000 – 700,000 newly diagnosed cases of heart failure are estimated each year in the US alone2. Roughly half of these new cases will result in death within five years. Heart failure exacts a monetary toll on the country as well. The costs for care and treatment (including drugs) and missed days of work total $32 billion yearly and are expected to reach over $57 billion in just over a decade3, 4. In the past five years, just one new/novel drug has been registered with a regulatory authority for approval. That drug, Novartis’ serelaxin, was recently given a unanimous vote of no confidence by the FDA Cardiovascular and Renal Drugs Advisory Committee for an acute heart failure indication5. Three other compounds (ivabradine, bisoprolol, valsartan + hydrochlorothiazide) with previous approvals in other indications such as hypertension and angina were also registered/approved for heart failure. This paper will examine the landscape of pharmaceutical industry new drug development and clinical trial activity in heart failure.
Within Citeline’s Pharmaprojects database, there are currently 85 compounds in development (preclinical
through preregistration) by industry for heart failure. Bayer and Servier lead all companies in overall drug
development with six and five compounds respectively (see Figure 1). Pfizer is next with three, and 14
companies have two drugs. While Novartis is among those with just two drugs in the pipeline for heart
failure, both are Phase III and they recently received positive news that one, LCZ-696, significantly reduced
cardiovascular mortality versus treatment with an ace inhibitor6. This could potentially make up for the
previously mentioned setback with serelaxin.
1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;14:30–41. doi: 0.1038/nrcardio.2010.165.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033496/#R2
2. Heart Failure Society of America http://www.hfsa.org/heart_failure_facts.asp
3. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm
4. AHA Policy Statement -Forecasting the Future of Cardiovascular Disease in the United States; Circulation. 2011; 123: 933-944 http://circ.ahajournals.org/content/123/8/933/T2.expansion.html
5. http://www.medpagetoday.com/Cardiology/CHF/44979
6. http://www.forbes.com/sites/larryhusten/2014/04/01/a-new-novartis-heart-failure-drug-might-be-a-blockbuster/
0
1
2
3
4
5
6
7
Bayer
Serv
ier
Pfizer
Amgen
Biohear
t
Cardio3 B
ioScien
ces
Cardioxy
l
Coreth
erap
ix
Cytokin
etics
GlaxoSm
ithKlin
e
John
son &
John
son
Ligan
d
Lone
Star
Hea
rt
Mer
ck &
Co
Novarti
s
Sano
fi
Trev
ena
# of
com
pou
nds
Figure 1. Heart Failure Drugs in Development
Source: Pharmaprojects®, Citeline April 2014
PharmaprojectsPharma intelligence |
3
3
Of the 85 drugs in development, 23 are in Phase II and 12 in Phase III (see Tables 1 and 2). 23% of these
products (three in Phase III and five in Phase II) are cellular therapies. While cell therapies have shown
some promise in heart failure, there has been some doubt cast on the true efficacy as a recent analysis has
shown that the effect on a major heart failure endpoint, left ventricular ejection fraction, has been minimal7.
A brief glance at the Phase III pipeline shows a dearth of innovation specific to heart failure. Just three of
the 12 compounds are new, non-cell therapy products. The remainder are older drugs already approved
for other indications or reformulations of drugs already approved for heart failure. Innovation looks a bit
better in Phase II as 15 of the 23 compounds are new, non-cell therapies. Included in this new research
are three targeted gene therapies from Juventas, Celladon, and Renova.
7. Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis BMJ 2014;348:g2688 http://www.bmj.com/content/348/bmj.g2688
table 1. Phase iii Pipeline
PriMary Drug naMe coMPanies MechanisM oF action
pioglitazone hydrochloride Takeda Thiazolidinedione
levocarnitine, Sigma-Tau Sigma-TauCarnitine O-acetyltransferase stimulant
aliskiren Novartis Renin inhibitor
lixivaptanPfizer Cornerstone
Vasopressin 2 antagonist
urodilatin Cardiorentis Atrial natriuretic peptide agonist
LCZ-696 NovartisAngiotensin II 1 antagonist Membrane metallo endopeptidase inhibitor
autologous myoblast cell therapy, Bioheart
Bioheart Stem cells/cell therapy
mesenchymal precursor cells, allogenic, CV, Mesoblast
Mesoblast Teva
Stem cells/cell therapy
ivabradine MR ServierSodium channel antagonist Potassium channel antagonist HCN channel antagonist
carvedilol sulfate, Jiangsu HengRui Medicine
Jiangsu Hengrui Medicine
Beta 1 adrenoreceptor antagonistBeta 2 adrenoreceptor antagonistAlpha 1 adrenoreceptor antagonistReducing agent
carvedilol ER, InnoPharmaxInnoPharmax TSH Biopharm
Alpha 1 adrenoreceptor antagonistBeta 1 adrenoreceptor antagonistBeta 2 adrenoreceptor antagonist
bone marrow-derived cardiopoi-etic cells, Cardio3
Cardio3 BioSciences Stem cells/cell therapy
PharmaprojectsPharma intelligence |
4
4
table 2. Phase ii Pipeline
PriMary Drug naMe coMPanies MechanisM oF action
testosterone patch, female Actavis Testosterone receptor agonist
ranolazine GileadPartial fatty acid oxidation inhibitorSodium channel antagonist
tenapanorArdelyx AstraZeneca
Sodium/hydrogen exchange inhibitor
mesenchymal bone marrow-de-rived stem cells, Stemedica-1
Stemedica CardioCell
Stem cells/cell therapy
autologous muscle derived cells, Cook Medical
Cook Medical Stem cells/cell therapy
vericiguat Bayer Guanylate cyclase stimulant
TRV-120027 Trevena Angiotensin II 1 antagonist
TRC-4186 Torrent Pharmaceuticals Glycosylation inhibitor
S-38844 ServierUnidentified pharmacological activity
omecamtiv mecarbilCytokinetics Amgen
Unidentified pharmacological activity
JVS-100 Juventas TherapeuticsStromal cell-derived factor 1 agonist
JNJ-54452840 Johnson & Johnson Beta 1 adrenoreceptor antagonist
istaroxime CVie Therapeutics Na+ K+ transporting ATPase inhibitor
finerenone Bayer Aldosterone antagonist
endometrial regenerative cells, Medistem
Medistem Stem cells/cell therapy
CLP-1001 Sorbent TherapeuticsOsmosis stimulant (non-diuretic)Chelating agent
CHF gene therapy, Targeted Genetics
AmpliPhi Biosciences Celladon
ATPase stimulant
carvedilol CR, EgaletEgalet RedHill Biopharma
Beta 1 adrenoreceptor antagonistBeta 2 adrenoreceptor antagonistAlpha 1 adrenoreceptor antagonistReducing agent
BAY-1067197 Bayer Adenosine A1 receptor agonist
allogeneic CDCs (intracardiac), Capricor
Capricor Therapeutics Johnson & Johnson
Stem cells/cell therapy
aladorianArmgo PharmaServier
Calcium channel antagonist
adipose-derived stem cells, Bioheart
Bioheart Stem cells/cell therapy
Ad5.hAC6 Renova Therapeutics Adenylate cyclase 6 stimulant
PharmaprojectsPharma intelligence |
5
0
2
4
6
8
10
12
Bayer
Novarti
s
Biohear
t
Pfizer
Serv
ier
Cellad
on
John
son &
John
son
Cytori
Ther
apeu
tics
GlaxoSm
ithKlin
e
NeoSt
em
# of
Tri
als
Figure 2. Heart Failure Trials by Company and Phase
III
II/III
II
I/II
I
5
Citeline’s Trialtrove database tracks clinical trials that are disclosed in the public domain. As of May 2014,
there were 114 industry sponsored Phase I – III clinical trials for heart failure known to be taking place
globally8. A look at the ongoing industry activity indicates that Bayer again leads all companies, with
Novartis and Bioheart right behind followed by Pfizer and Servier. A closer look reveals that all of Pfizer’s
clinical trials are in Phase III. For the subset of acute heart failure, Novartis leads with four trials followed by
Otsuka with two, and Servier, and Johnson & Johnson with one each.
Source: Trialtrove®, May 2014 Citeline
8. Citeline data is obtained from over 30,000 sources in the public domain. Trial reporting rules and regulations differ among countries around the world and not all trial activity in some countries may be recorded.
PharmaprojectsPharma intelligence |
6
6
Using Citeline’s Sitetrove Investigator Prioritization feature (see Table 3), our analysis indicates that of the
nearly 800 identified investigators for active heart failure trials, industry sponsors are utilizing the most
attractive investigators that have the highest potential to perform well in clinical trials just 13% of the time.
And just 17% of the 600 currently available top tier investigators are being utilized for these trials. Nearly
40% of the active investigators for industry sponsored heart failure trials are categorized as Tier 3, or
lowest performing investigators recruiting the fewest numbers of patients. These figures indicate that
sponsors are missing the opportunity to enroll patients in trials quickly and thus are spending valuable
R & D money on poorly performing investigators.
Source: Sitetrove®, May 2014 Citeline
table 3. investigator Prioritization Matrix
tiers Matching search across entire Disease
Tier 1 102 600
Tier 2 389 5814
Tier 3 305 10406
0
10
20
30
40
50
60
United
Stat
es
German
y Ita
ly
Poland
Spain
Hungar
y
Nethe
rland
s
Czech
Rep
ublic
Austra
lia
Canad
a
# of
Tri
als
Figure 3. Heart Failure Trials by Phase and Location
III
II/III
II
I/II
I
Source: Trialtrove®, May 2014 Citeline
The vast majority of ongoing clinical trial activity is occurring in the United States as there are just over 50
trials taking place there (see Figure 3). The remaining top 10 locations are spread somewhat evenly across
Europe, Canada, and Australia. Given the global prevalence of heart failure, it is surprising only three Asian
countries (China-20th, South Korea-22nd, and Japan-25th) make the top 30 list for locations, none with
more than nine active trials.
PharmaprojectsPharma intelligence |
7
7
More innovation, better location/investigator selection, stronger stem cell therapy trials needed
In summary, the heart failure landscape shows promise, although there appears to be more potential for
innovation in the Phase II pipeline. Cell therapies account for a large portion of the drugs in development,
but more and better run trials may be needed to convince the healthcare community of their viability.
While Bayer leads all companies in total development compounds, Novartis may be in position to be a
leader in this area if they can capitalize on two Phase III drugs as well as make any necessary modifications
to the serelaxin program. Heart failure clinical trial activity is heavily concentrated in the United States and
there are opportunities to conduct more trials globally, especially in Asia. Industry sponsors are under
utilizing the best performing investigators for heart failure trials.